

IN THE CLAIMS:

Please cancel claims 1-35, all claims presently pending, and enter new claims 36-61 as shown.

Claims 1-35 (Canceled)

Claim 36. (New) An injectable chemotherapeutic composition for implantation in a patient, said composition comprising:

 a bioabsorbable collagenous biomaterial, said bioabsorbable collagenous biomaterial effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted;

 said bioabsorbable collagenous biomaterial provided in an injectable form;

 a radiopaque powder material; and

 a chemotherapeutic agent;

 whereby said injectable chemotherapeutic composition comprising the bioabsorbable collagenous biomaterial, radiopaque powder material and chemotherapeutic agent is implantable by injection at a site to deliver said chemotherapeutic agent, to promote remodeling of patient tissue, and can also be visualized radiographically.

Claim 37. (New) The injectable chemotherapeutic composition of claim 36, wherein said bioabsorbable collagenous biomaterial is provided in a substantially spherical form.

Claim 38. (New) The injectable chemotherapeutic composition of claim 36, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, basement membrane, and amniotic membrane.

Claim 39. (New) The injectable chemotherapeutic composition of claim 37, wherein said bioabsorbable collagenous biomaterial comprises a material selected from

the group consisting of submucosa, pericardium, basement membrane, and amniotic membrane.

Claim 40. (New) The injectable chemotherapeutic composition of claim 38, wherein said bioabsorbable collagenous biomaterial comprises submucosa.

Claim 41. (New) The injectable chemotherapeutic composition of claim 36, wherein said radiopaque powder includes a material selected from the group consisting of tantalum, bismuth, and barium.

Claim 42. (New) The injectable chemotherapeutic composition of claim 41, wherein said radiopaque powder includes tantalum.

Claim 43. (New) The injectable chemotherapeutic composition of claim 36, which comprises a suspension of a comminuted amount of the collagenous biomaterial.

Claim 44. (New) The injectable chemotherapeutic composition of claim 43, wherein the collagenous biomaterial comprises submucosa.

Claim 45. (New) A radiopaque, implantable biomaterial device, comprising:
a bioabsorbable collagenous biomaterial, said bioabsorbable collagenous biomaterial effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted, said bioabsorbable collagenous biomaterial including at least one biotropic agent selected from the group consisting of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan;
a radiopaque powder material received on the surface of the bioabsorbable collagenous biomaterial.

Claim 46. (New) The radiopaque, implantable biomaterial device of claim 45, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, basement membrane, and amniotic membrane.

Claim 47. (New) The radiopaque, implantable biomaterial device of claim 46, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa and pericardium.

Claim 48. (New) The radiopaque, implantable biomaterial device of claim 47, wherein said bioabsorbable collagenous biomaterial comprises submucosa.

Claim 49. (New) The radiopaque, implantable biomaterial device of claim 47, wherein said radiopaque powder includes a material selected from the group consisting of tantalum, bismuth, and barium.

Claim 50. (New) The radiopaque, implantable biomaterial device of claim 49, wherein said radiopaque powder includes tantalum.

Claim 51. (New) The radiopaque, implantable biomaterial device of claim 50, wherein the collagenous biomaterial comprises submucosa.

Claim 52. (New) The radiopaque, implantable biomaterial device of claim 51, wherein the collagenous biomaterial comprises porcine small intestine submucosa.

Claim 53. (New) The radiopaque, implantable biomaterial device of claim 45, wherein said collagenous biomaterial is provided in injectable form.

Claim 54. (New) A radiopaque, implantable biomaterial device, comprising:
a multi-layer bioabsorbable collagenous biomaterial, said multi-layer bioabsorbable collagenous biomaterial effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted; and
a radiopaque marker disposed in between layers of said multi-layer bioabsorbable collagenous biomaterial.

Claim 55. (New) The radiopaque, implantable biomaterial device of claim 54, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, basement membrane, and amniotic membrane.

Claim 56. (New) The radiopaque, implantable biomaterial device of claim 55, wherein said bioabsorbable collagenous biomaterial comprises submucosa.

Claim 57. (New) The radiopaque, implantable biomaterial device of claim 54, wherein said radiopaque marker comprises a radiopaque powder including a material selected from the group consisting of tantalum, bismuth, and barium.

Claim 58. (New) The radiopaque, implantable biomaterial device of claim 57, wherein said radiopaque powder includes tantalum.

Claim 59. (New) The radiopaque, implantable biomaterial device of claim 58, wherein the collagenous biomaterial comprises porcine submucosa.

Claim 60. (New) The radiopaque, implantable biomaterial device of claim 59, wherein the collagenous biomaterial comprises porcine small intestine submucosa.

Claim 61. (New) The radiopaque, implantable biomaterial device of claim 54, wherein said collagenous biomaterial is provided in injectable form.